CSF biomarkers for Alzheimer’s disease: Current utility and potential future use

Por Holtzman, David M.
Publicado em 2011

A surrogate marker for Aβ42 production in the CNS

Por Holtzman, David M
Publicado em 2009

In situ atomic force microscopy study of Alzheimer’s β-amyloid peptide on different substrates: New insights into mechanism of β-sheet formation

Por Kowalewski, Tomasz, Holtzman, David M.
Publicado em 1999

Critical Issues for Successful Immunotherapy in Alzheimer’s Disease: Development of Biomarkers and Methods for Early Detection and Intervention

Por Tarawneh, Rawan, Holtzman, David M.
Publicado em 2009

Biomarkers in translational research of Alzheimer’s Disease

Por Tarawneh, Rawan, Holtzman, David M.
Publicado em 2010

The Clinical Problem of Symptomatic Alzheimer Disease and Mild Cognitive Impairment

Por Tarawneh, Rawan, Holtzman, David M.
Publicado em 2012

Origins of Alzheimer's Disease: Reconciling CSF biomarker and neuropathology data regarding the temporal sequence of Aβ and tau involvement

Por Musiek, Erik S., Holtzman, David M.
Publicado em 2012

B-RAF unlocks axon regeneration

Por Cavalli, Valeria, Holtzman, David M.
Publicado em 2014

The Ultrastructural Identity of Alzheimer's Pathology: Lessons from Animal Models

Por Dikranian, Krikor, Holtzman, David M.
Publicado em 2014

Three Dimensions of the Amyloid Hypothesis: Time, Space, and “Wingmen”

Por Musiek, Erik S., Holtzman, David M.
Publicado no Nat Neurosci (2015)

Mechanisms Linking Circadian Clocks, Sleep, and Neurodegeneration

Por Musiek, Erik S., Holtzman, David M.
Publicado no Science (2016)

Antibody Therapeutics Targeting Aβ and Tau

Por Gallardo, Gilbert, Holtzman, David M.
Publicado no Cold Spring Harb Perspect Med (2017)

Interplay between innate immunity and Alzheimer’s disease: APOE and TREM2 in the spotlight

Por Shi, Yang, Holtzman, David M.
Publicado no Nat Rev Immunol (2018)

Bidirectional relationship between sleep and Alzheimer’s disease: role of amyloid, tau, and other factors

Por Wang, Chanung, Holtzman, David M.
Publicado no Neuropsychopharmacology (2019)

Amyloid β and Alzheimer disease therapeutics: the devil may be in the details

Por Cirrito, John R., Holtzman, David M.
Publicado em 2003

Morris water maze search strategy analysis in PDAPP mice before and after experimental traumatic brain injury

Por Brody, David L., Holtzman, David M.
Publicado em 2005

Active and Passive Immunotherapy for Neurodegenerative Disorders

Por Brody, David L., Holtzman, David M.
Publicado em 2008

Cerebrospinal fluid biomarkers of Alzheimer’s disease

Por Fagan, Anne M, Holtzman, David M
Publicado em 2010

Biomarker Modeling of Alzheimer's Disease

Por Jack, Clifford R, Holtzman, David M
Publicado em 2013

Recent Advances from the Bench Toward the Bedside in Alzheimer's Disease

Por Macauley, Shannon L., Holtzman, David M.
Publicado no EBioMedicine (2015)